WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Legalcategory GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln October 9, 2024 Healthcare & Pharmaceuticalscategory GSK, Pfizer RSV vaccine sales fall in US as millions fewer ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

Based on the data collected, dental staff can now offer improved recommendations to ... The material science-based study carried out on behalf of GSK Consumer Healthcare (since renamed Haleon) was ...

For the last few months, GSK's Augmentin has continued to maintain its top selling brand position. "Augmentin continues to be GSKs hallmark of quality and trust with health care professionals (HCP ...

The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...